GleamWall
中文EN

RDHL RedHill Biopharma Ltd. IFRS

Pharmaceutical Preparations · Nasdaq · SEC CIK 1553846

Financial factors as of 2021-12-31 (FY2021), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY33.2%
TTM net income YoY-28.3%
TTM EPS YoY0.0%
Revenue 3-yr CAGR117.3%
Net income 3-yr CAGR—

Margins

Gross margin42.4%
Operating margin-94.6%
Net margin-114.0%
FCF margin-76.0%
EBITDA margin—

Returns

ROE-859.7%
ROA-54.1%
ROIC (approx.)-99.4%
Asset turnover0.47x

Leverage & solvency

Liabilities / assets95.1%
Debt / equity9.42x
Current ratio1.09x
Interest coverage-4.87x

Cash quality & payout

Operating cash flow / net income0.67x
Accruals ratio-18.1%
Payout ratio—
Capex / revenue0.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2022Q2*2022-06-302021Q2*2021-06-302020Q2*2020-06-302019Q2*2019-06-302018Q2*2018-06-302017Q2*2017-06-30
Income statement
Revenue$18.35M$21.50M$20.90M$1.56M$2.35M$483,000
Cost of revenue$8.99M$10.59M$14.19M$425,000$725,000$272,000
Gross profit$9.35M$10.91M$6.71M$1.14M$1.62M$211,000
R&D expense$1.47M$10.33M$3.21M$6.97M$6.04M$8.43M
SG&A expense$7.76M$10.23M$6.03M$2.40M$2.02M$1.94M
Operating income-$9.16M-$24.89M-$12.50M-$12.38M-$9.56M-$13.54M
Interest expense$4.21M$4.25M$3.65M$74,000$1.72M$7,000
Net income-$11.71M-$29.12M-$16.05M-$10.91M-$11.12M-$11.02M
EPS (basic)-0.02-0.060.040.040.050.06
EPS (diluted)-0.02-0.060.040.040.050.06
Balance sheet
Cash & equivalents$26.99M$51.82M$22.27M$8.99M$5.56M$15.32M
Receivables$33.76M$30.10M$18.57M$963,000$1.80M—
Inventory$11.72M$8.76M$4.75M$1.83M$690,000—
Current assets$91.27M$98.49M$61.13M$39.97M$32.22M—
PP&E, netmay include right-of-use assets (IFRS)$616,000$506,000$345,000$250,000$200,000—
Intangibles$68.74M$84.22M$79.52M$5.32M$5.29M—
Total assets$167.97M$203.67M$166.37M$49.70M$37.85M—
Current liabilities$166.41M$79.17M$35.87M$14.05M$9.88M—
Short-term debt$85.51M—————
Long-term debt—$83.16M$79.19M———
Total debt—$83.16M$79.19M———
Total liabilities$179.91M$174.09M$131.78M$17.79M$11.94M—
Shareholders' equity-$11.94M$29.58M$34.59M$31.90M$25.91M$48.80M
Net debt—$31.34M$56.92M———
Cash flow statement
Operating cash flow-$16.58M-$18.90M-$15.03M-$10.45M-$8.40M-$9.73M
Capital expenditure$163,000$3,000$20,000$128,000$2,000$102,000
Free cash flow-$16.74M-$18.90M-$15.05M-$10.58M-$8.40M-$9.83M
Investing cash flow-$163,000-$3.50M-$49.80M-$3.39M$6.46M-$4.87M
Financing cash flow$14.92M-$1.77M$5.46M-$199,000—$175,000
Stock-based compensation$618,000$5.27M$623,000$937,000$733,000$705,000

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.